

Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort

Harun Kundi^{1,2}, Jeffrey J. Popma^{1,2}, Matthew R. Reynolds^{2,3}, Jordan B. Strom¹, Duane S. Pinto¹, Linda R. Valsdottir¹, Changyu Shen¹, Eunhee Choi¹, and Robert W. Yeh^{1,2*}

¹Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, 375 Longwood Ave, Fourth Floor, Boston, MA 02215, USA; ²Baim Institute for Clinical Research, 930 Commonwealth Avenue #3, Boston, MA 02215, USA; and ³Division of Cardiology, Lahey Hospital & Medical Center, 41 Burlington Mall Road, Burlington, MA 01805, USA

Received 30 September 2018; revised 29 November 2018; editorial decision 7 February 2019; accepted 13 March 2019; online publish-ahead-of-print 11 April 2019

See page 2240 for the editorial comment on this article (doi: 10.1093/eurheartj/ehz382)

Aims

We sought to identify the prevalence and related outcomes of frail individuals undergoing transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR).

Methods and results

Patients aged 65 and older were included in the study if they had at least one procedural code for transcatheter mitral valve repair or TAVR between 1 January 2016 and 31 December 2016 in the Centers for Medicare and Medicaid Services Medicare Provider and Review database. The Hospital Frailty Risk Score, an International Classification of Diseases, Tenth Revision (ICD-10) claims-based score, was used to identify frailty and the primary outcome was all-cause 1-year mortality. A total of 3746 (11.6%) patients underwent transcatheter mitral valve repair and 28 531 (88.4%) underwent TAVR. In the transcatheter mitral valve repair and TAVR populations, respectively, there were 1903 (50.8%) and 14 938 (52.4%) patients defined as low risk for frailty (score <5), 1476 (39.4%) and 11 268 (39.5%) defined as intermediate risk (score 5–15), and 367 (9.8%) and 2325 (8.1%) defined as high risk (score >15). One-year mortality was 12.8% in low-risk patients, 29.7% in intermediate-risk patients, and 40.9% in high-risk patients undergoing transcatheter mitral valve repair (log rank $P < 0.001$). In patients undergoing TAVR, 1-year mortality rates were 7.6% in low-risk patients, 17.6% in intermediate-risk patients, and 30.1% in high-risk patients (log rank $P < 0.001$).

Conclusions

This study successfully identified individuals at greater risk of short- and long-term mortality after undergoing transcatheter valve therapies in an elderly population in the USA using the ICD-10 claims-based Hospital Frailty Risk Score.

Keywords

Claims data • Frailty • Transcatheter valve therapies

Introduction

Frailty is conceptually defined as a multisystem clinical syndrome that results in a decreased physiological reserve and an increased vulnerability to stressors.¹ Regardless of definition, frailty is a key factor in identifying older patients' potential for improvement after transcatheter valve therapies.² Prior studies have shown that both short- and

long-term mortality rates are significantly higher after transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR) in frail patients.^{3–9} National guidelines strongly recommend an objective evaluation of frailty to optimize patient selection, but the range of available measures raises issues with consistency.^{10,11} In clinical practice, frailty is not often measured due to the lack of consensus surrounding frailty assessment tools,¹² and there are divergent

* Corresponding author. Tel: 617-632-7653, Fax: 617-632-7698, E-mail: ryeh@bidmc.harvard.edu

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

prevalence estimates and effect sizes reported across different studies.^{4,13}

Since 2012, the transcatheter valve therapy (TVT) registry has reported the outcomes of patients undergoing procedures including TAVR and transcatheter mitral valve repair in the USA.¹⁴ This robust registry allows for transparent analysis of patient outcomes after these procedures. However, the prospective collection of information on frailty is time-consuming and may not always be feasible. In addition, registries may misrepresent frailty status and prevalence by focusing on a limited definition of frailty, not including all hospitals, and defining frailty according to a single point in time. Administrative claims represent an alternative source of data by which frailty might be more easily assessed.^{15,16} However, prior claims-based classification systems may have been insufficiently granular to adequately characterize complex conditions such as frailty. The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), which was introduced in many countries including the USA in 2015, greatly increased the number of codes that are available for use. Recently, an ICD-10-based frailty score has been developed and validated among the elderly population in the UK.¹⁷ No studies have yet evaluated whether the ICD-10-CM-based Hospital Frailty Risk Score can be used to evaluate frailty among patients undergoing valvular heart disease interventions. Therefore, in this study, we sought to identify the prevalence of frailty based on the recently validated ICD-10-based Hospital Frailty Risk Score, and measure the impact of frailty on outcomes of individuals undergoing TAVR or transcatheter mitral valve repair using data from the US Centers for Medicare and Medicaid Services (CMS) Medicare Provider Analysis and Review (MedPAR) data, which contains a longitudinal record of patient hospitalizations.

Materials and methods

Study population

The CMS MedPAR database utilized for this study is a 100% sample of administrative billing claims for inpatient hospitalizations, and has been used previously to study national patterns of procedure utilization in the USA.^{18,19} Patients aged 65 and older were included in the study if they had at least one procedural code for transcatheter mitral valve repair (ICD-10-CM code O2UG3JZ) or TAVR (ICD-10-CM codes O2RF38H or O2RF38Z), between 1 January 2016 and 31 December 2016.

Covariates

Baseline covariates were ascertained using secondary diagnosis codes that were coded as 'present on admission' during the index hospitalization (i.e. the hospitalization for the initial procedure), as well as from principal and secondary diagnosis codes from all hospitalizations at least 3 months prior to the date of admission for the index hospitalization in each patient (from 1 October 2015 to 1 October 2016). Elixhauser (see [Supplementary material](#) online, *Table S1*) and Charlson (see [Supplementary material](#) online, *Table S2*) comorbidity indices, both of which are validated summary comorbidity measures that have been previously shown to predict mortality in the Medicare population,^{20,21} were measured for each patient.

Definition of frailty

To identify frail individuals, we calculated the Hospital Frailty Risk Score for each individual. This score was recently developed and validated in a

large, older (≥ 75 years) population in the UK, and is based on diagnoses associated with high resource use.¹⁷ It has not been used to describe frailty in the USA. For each patient, we calculated the Hospital Frailty Risk Score based on 109 ICD-10 diagnostic codes (the first three characters) from all hospitalizations occurring at least 3 months prior to the date of admission for the index hospitalization or using secondary diagnosis codes that were coded as 'present on admission' during the index hospitalization in each patient. The full list of diagnoses is shown in [Supplementary material](#) online, *Table S3*. We categorized individuals into risk categories based on their calculated Hospital Frailty Risk Score. Individuals were categorized as low (< 5), intermediate (5–15), and high risk (> 15) for frailty based on previously published cut-points, and patients in the intermediate-risk and high-risk categories were defined as frail.¹⁷

Outcomes

The primary outcome was all-cause 1-year mortality, determined through linkage of the MedPAR files to the Medicare Beneficiary Summary File, which includes vital status information. Time to death was calculated as the time period between the date of the index procedure and the date of death. Additionally, we identified long hospital stays (defined as > 10 days in hospital), and 30-day mortality. Furthermore, we determined the number of rehospitalizations (defined as '0', '1', and ' ≥ 2 '); all-cause rehospitalization rates within 1 year; and rehospitalizations due to acute myocardial infarction, acute heart failure, acute kidney failure, stroke or transient ischaemic attack, and acute post-haemorrhagic anaemia as secondary outcomes in patients discharged alive from the index procedure. Transfers to other hospitals were linked to a single index hospitalization. Time to rehospitalization was calculated as the time period between the date of discharge from the index hospitalization and the date of admission for the first subsequent hospitalization. Patients were censored if they were no longer enrolled in Medicare according to the denominator file as of 31 December 2016, which marked the end of the follow-up period for time to rehospitalization.

Statistical analysis

Continuous variables are presented as means and standard deviations or medians and inter-quartile ranges, and categorical variables are presented as counts and percentages. Restricted cubic spline curves with five knots were used to show the non-linear associations between the Hospital Frailty Risk Score and 1-year mortality. Multivariable Cox regression models were used to determine the impact of frailty (continuous and categorical) on all-cause 1-year mortality. Competing risk Cox regression analyses were used to show the performance of frailty in all-cause rehospitalization and each subgroup of rehospitalization, and to show cumulative incidence rates of rehospitalization, since mortality was a competing risk for rehospitalization. Patients who died within the study period (before 31 December 2016) represented a competing risk since they could not be rehospitalized after the date of death. Since different measures of comorbidity may be collinear with the frailty score, we used variance inflation factors (VIF) to test whether there are collinearities among the Hospital Frailty Risk Score, Elixhauser and Charlson comorbidity indices. Models were adjusted for age, sex, and Elixhauser and Charlson comorbidity indices. Multivariable Cox regression models were used to investigate the interaction between the Hospital Frailty Risk Score and transcatheter valve therapies. Harrell's c-statistic was used to assess model discrimination, and the improvement in discrimination with the addition of the Hospital Frailty Risk Score was assessed by the change in the c-statistic and the DeLong test.²² An integrated discrimination improvement (IDI) test was also used to assess discrimination improvement.²³ Unadjusted cumulative incidence curves were created to plot

Table 1 List of ICD-10 codes, their prevalence in each group, and the number of points that each variable contributes to the creation of the Hospital Frailty Risk Score in patients undergoing transcatheter mitral valve repair and transcatheter aortic valve replacement

		Transcatheter mitral valve repair, n = 3746, n (%)	Transcatheter aortic valve replacement, n = 28 531, n (%)	Points
G81	Hemiplegia	31 (0.8)	365 (1.3)	4.4
G30	Alzheimer's disease	23 (0.6)	312 (1.1)	4.0
I69	Sequelae of cerebrovascular disease (secondary codes)	96 (2.6)	993 (3.5)	3.7
R29	Other symptoms and signs involving the nervous and musculoskeletal systems (R29.6 Tendency to fall)	53 (1.4)	534 (1.9)	3.6
N39	Other disorders of urinary system (includes urinary tract infection and urinary incontinence)	410 (10.9)	3080 (10.8)	3.2
F05	Delirium, not induced by alcohol and other psychoactive substances	49 (1.3)	479 (1.7)	3.2
W19	Unspecified fall	6 (0.2)	34 (0.1)	3.2
S00	Superficial injury of head	24 (0.6)	161 (0.6)	3.2
R31	Unspecified haematuria	162 (4.3)	924 (3.2)	3.0
B96	Other bacterial agents as the cause of diseases classified to other chapters (secondary code)	163 (4.4)	1186 (4.2)	2.9
R41	Other symptoms and signs involving cognitive functions and awareness	102 (2.7)	891 (3.1)	2.7
R26	Abnormalities of gait and mobility	212 (5.7)	1559 (5.5)	2.6
I67	Other cerebrovascular diseases	30 (0.8)	319 (1.1)	2.6
R56	Convulsions, not elsewhere classified	20 (0.5)	141 (0.5)	2.6
R40	Somnolence, stupor, and coma	11 (0.3)	124 (0.4)	2.5
T83	Complications of genitourinary prosthetic devices, implants, and grafts	35 (0.9)	200 (0.7)	2.4
S06	Intracranial injury	7 (0.2)	99 (0.3)	2.4
S42	Fracture of shoulder and upper arm	9 (0.2)	73 (0.3)	2.3
E87	Other disorders of fluid, electrolyte, and acid-base balance	1176 (31.4)	7677 (26.9)	2.3
M25	Other joint disorders, not elsewhere classified	78 (2.1)	547 (1.9)	2.3
E86	Volume depletion	245 (6.5)	1558 (5.5)	2.3
R54	Senility	149 (4.0)	1523 (5.3)	2.2
F03	Unspecified dementia	162 (4.3)	1595 (5.6)	2.1
W18	Other fall on same level	1 (<1)	19 (0.1)	2.1
Z75	Problems related to medical facilities and other health care	4 (0.1)	12 (<1)	2.0
F01	Vascular dementia	5 (0.1)	124 (0.4)	2.0
S80	Superficial injury of lower leg	10 (0.3)	84 (0.3)	2.0
L03	Cellulitis	114 (3.0)	699 (2.4)	2.0

The score presents the top 28 codes, each of which contributes ≥ 2 points. (All covariates are presented in [Supplementary material online, Table S3](#).)

time to event, stratified by risk category. All statistical analyses were performed in STATA version 15.0 (Stata Corporation, College Station, TX, USA) or SAS version 9.4 (SAS Institute, Cary, NC, USA) using a two-tailed alpha < 0.05 to define statistical significance.

Results

Overall results and frailty

A total of 32 986 patients treated with TAVR or transcatheter mitral valve repair were identified during the study period. After excluding 709 patients aged < 65 years, a total of 32 277 patients were ultimately included in the analytic sample. Of these, 3746 underwent transcatheter mitral valve repair and 28 531 underwent TAVR. The prevalence of the 28 ICD-10 codes contributing the largest point

totals (minimum two points) towards the Hospital Frailty Risk Score are presented in [Table 1](#) (all covariates are presented in [Supplementary material online, Table S3](#)). 'Other disorders of fluid, electrolyte and acid-base balance' (31.4% and 26.9%), and 'other disorders of urinary system' including urinary tract infection and urinary incontinence (10.9% and 10.8%), were the most frequently diagnosed codes in both the transcatheter mitral valve repair and TAVR groups, respectively. Baseline characteristics of patients are presented in [Table 2](#). The mean age of TVT recipients was 80.1 ± 8.9 years in the group undergoing transcatheter mitral valve repair, and in 81.5 ± 8.1 in the group undergoing TAVR. The majority of patients were male in both transcatheter mitral valve repair (51.8%) and TAVR (53.6%) groups.

There were 1903 (50.8%) and 14 938 (52.4%) patients defined as low risk using a cut-point score of < 5 ; while 1476 (39.4%) and 11 268

Table 2 Characteristics of patients after transcatheter mitral valve repair and transcatheter aortic valve replacement

	Transcatheter mitral valve repair (n = 3746)	Transcatheter aortic valve replacement (n = 28 531)
Age, mean (SD)	80.1 (8.9)	81.5 (8.1)
Male, no. of pts	1941 (51.8%)	15 304 (53.6%)
Charlson Index, mean (SD)	2.9 (1.9)	3.1 (2.0)
Elixhauser Comorbidity Index, mean (SD)	5.7 (1.9)	5.8 (1.9)
Hospital Frailty Index, mean (SD)	6.6 (6.1)	6.3 (5.7)
Hospital Frailty Risk Category		
Low risk (<5), no. of pts	1903 (50.8%)	14 938 (52.4%)
Intermediate risk (5–15), no. of pts	1476 (39.4%)	11 268 (39.5%)
High risk (>15), no. of pts	367 (9.8%)	2325 (8.1%)
Frail (≥ 5 Hospital Frailty Index), no. of pts	1843 (49.2%)	13 593 (47.6%)

(39.5%) were defined as intermediate risk (5–15), and 367 (9.8%) and 2325 (8.1%) were defined as high risk (>15) in the transcatheter mitral valve and TAVR populations, respectively. The mean Hospital Frailty Risk Score was 6.6 ± 6.1 in the transcatheter mitral valve repair population and 6.3 ± 5.7 in the TAVR population.

Outcomes

All outcomes including long length of stay, crude 30-day mortality rate, 1-year mortality rate, and rehospitalization rates for all pre-specified subgroups were consistently and significantly greater in higher Hospital Frailty Risk Score categories for patients undergoing both transcatheter mitral valve repair and TAVR (Table 3). The distribution of the Hospital Frailty Risk Score in the transcatheter mitral valve repair and TAVR populations are presented in [Take home figure](#). The 1-year mortality rate increased with increasing values of the score in patients undergoing transcatheter mitral valve repair and TAVR ([Take home figure](#)). In Kaplan–Meier analysis (Figure 1), the 1-year mortality rate was 12.8% in the low-risk group, 29.7% in the intermediate-risk group, and 40.9% in the high-risk group for patients undergoing transcatheter mitral valve repair (log rank $P < 0.001$ for comparison between categories). In patients undergoing TAVR, 1-year mortality rates were 7.6% in the low-risk group, 17.6% in the intermediate-risk group, and 30.1% in the high-risk group (P -values < 0.001 by log-rank test). Kaplan–Meier estimates for time to rehospitalization in transcatheter mitral valve repair and TAVR patients are also presented in [Supplementary material](#) online, [Figure S1](#) and [S2](#), respectively.

The c-statistic for all-cause 1-year mortality without the Hospital Frailty Risk Score was 0.65 for mitral valve repair and 0.66 for TAVR. After adding the Hospital Frailty Risk Score, the c-statistics improved to 0.70 and 0.71, respectively (DeLong P -value < 0.001 for both). Furthermore, the IDI after addition of the frailty score was 0.033 ($P < 0.001$) for mitral valve repair and 0.024 ($P < 0.001$) for TAVR. The c-statistic for all-cause 1-year mortality using only the Hospital Frailty Risk Score (unadjusted) was 0.67 for mitral valve repair and 0.67 for TAVR.

There was no meaningful collinearity (mean VIF = 1.70) among the Hospital Frailty Risk Score (VIF = 1.16), Elixhauser comorbidity index (2.0) and Charlson comorbidity index (1.95). In multivariable Cox

regression analyses, after adjusting for age, gender, and Elixhauser and Charlson comorbidity indices, increasing Hospital Frailty Risk Score (1 point increase) was associated with increasing all-cause mortality (HR: 1.060 for transcatheter mitral valve repair and HR: 1.062 for TAVR) and rehospitalizations (HR: 1.061 for both procedures). These associations were also present when frailty was categorized into low, intermediate, and high-risk categories for both the transcatheter mitral valve repair and TAVR groups (Table 4). There was no interaction between Hospital Frailty Risk Score and transcatheter valve therapies on all defined outcomes (Table 4).

Discussion


This nationwide cohort study demonstrates that almost half of patients undergoing transcatheter valve therapies in the USA have intermediate or high frailty levels, according to a frailty scoring system recently derived and validated in administrative claims data. The addition of the ICD-10-based Hospital Frailty Risk Score effectively stratified patients undergoing valvular interventions based on their risk of multiple patient-oriented endpoints, including short- and long-term mortality, long length of stay, and all-cause rehospitalization, and provided predictive information significantly above commonly used claims-based comorbidity assessments. Our study adds to the existing literature suggesting that frailty is an important predictor of outcomes for patients with valvular heart disease who are scheduled to undergo catheter-based interventions. It also demonstrates that a novel ICD-10-based frailty score developed in a patient population over the age of 75 years in the UK can provide accurate prognostic information on patient frailty in a younger (≥ 65 years) population undergoing transcatheter valve therapies in the USA.

Our study expands on similar findings demonstrating that adding frailty to summary measures of comorbidities can improve the discrimination of 1-year mortality in the TAVR population.²⁴ However, the assessment of frailty and its exact prevalence remains unclear due to substantial disagreement among 35 existing frailty scales, including commonly used scales such those by Fried and Rockwood.²⁵ For example, the rate of disagreement among seven of these scales ranged between 35% and 74% in the largest prospective study to date

Table 3 Outcomes of patients after transcatheter mitral valve repair and transcatheter aortic valve replacement

	Transcatheter mitral valve repair (n = 3746)			Transcatheter aortic valve replacement (n = 28 531)		
	Low risk (n = 1903)	Intermediate risk (n = 1476)	High risk (n = 367)	Low risk (n = 14 938)	Intermediate risk (n = 11 268)	High risk (n = 2325)
Long length of stay, no. of pts (%)	40 (2.1)	210 (14.2)	119 (32.4)	404 (2.7)	1727 (15.3)	629 (27.1)
30-day mortality, no. of pts (%)	20 (1.1)	99 (6.7)	44 (12.0)	143 (1.0)	418 (3.7)	169 (7.3)
1-year mortality, no. of pts (%) ^a	244 (12.8)	439 (29.7)	150 (40.9)	1142 (7.6)	1978 (17.6)	701 (30.1)
n = 3674 (alive at discharge, index procedure)						
No. of rehospitalizations, n (%)	1305 (68.7)	740 (51.7)	133 (38.7)	10 481 (70.5)	5909 (53.8)	819 (36.7)
0	312 (16.4)	338 (23.6)	91 (26.5)	2487 (16.7)	2558 (23.3)	687 (30.8)
1	282 (14.8)	353 (24.7)	120 (34.9)	1893 (12.7)	2524 (23.0)	723 (32.4)
≥2	594 (47.9)	691 (72.9)	211 (81.3)	4380 (47.7)	5082 (68.5)	1410 (85.3)
All-cause rehospitalization (within 1-year), no. of pts, (%) ^a						
n = 28 111 (alive at discharge, index procedure)						
Rehospitalization (within 1-year) due to	25 (2.4)	35 (3.6)	16 (8.3)	218 (2.5)	336 (3.8)	104 (11.0)
Acute myocardial infarction, no. of pts, (%) ^a						
Acute heart failure, no. of pts, (%) ^a	277 (19.4)	350 (36.3)	117 (54.7)	1037 (10.3)	1598 (21.6)	486 (36.8)
Acute renal failure, no. of pts, (%) ^a	217 (16.7)	296 (36.6)	100 (51.3)	1029 (11.0)	1498 (22.8)	447 (42.9)
Transient ischaemic attack or stroke, no. of pts, (%) ^a	36 (2.0)	36 (3.5)	21 (4.7)	262 (2.6)	338 (3.6)	111 (12.1)
Acute post-haemorrhagic anaemia, no. of pts, (%) ^a	108 (7.7)	117 (10.1)	28 (12.7)	735 (8.0)	863 (10.6)	189 (15.4)

^aPercentages represent Kaplan–Meier cumulative event probability (Kaplan–Meier curves for rehospitalizations are presented in Supplementary material online, Figures S1 and S2).



Take home figure The distribution of the Hospital Frailty Risk Score and its association with 1-year mortality in the transcatheter mitral valve repair and transcatheter aortic valve replacement populations using restricted cubic spline plots. The vertical red dashed lines show thresholds for categorizing patients as low frailty risk (score <5), intermediate frailty risk (score 5–15), or high frailty risk (score >15). Since there were very few patients with a Hospital Frailty Risk Score of >30, those patients are classified into a single group.




Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and transcatheter aortic valve replacement populations.

specifically designed to investigate frailty in older patients undergoing TAVR.⁴ This range of estimates illustrates the challenge of using any one frailty scale to diagnose an individual as frail. Furthermore, prior studies suggest that in order to be used as a measure that captures

the dynamic nature of frailty, a continuous or ordinal scoring system might be better than a dichotomous one (frail vs. non-frail).²⁶ This idea is supported by our study findings, which demonstrate a graded increase in the risk of adverse events across most of the frailty-score

Table 4 Results of Cox multivariable regression models (adjusted for age, gender, Elixhauser and Charlson comorbidity indices)

	Transcatheter mitral valve repair		Transcatheter aortic valve replacement		P-value for interaction
	Hazard ratio (95% CIs)	P-value	Hazard ratio (95% CIs)	P-value	
All-cause mortality					
Hospital Frailty Risk Score	1.060 (1.050–1.070)	<0.001	1.062 (1.058–1.067)	<0.001	0.258
Hospital Frailty Risk Category		<0.001		<0.001	
Intermediate risk (5–15)	2.257 (1.858–2.743)	<0.001	1.931 (1.762–2.117)	<0.001	
High risk (>15)	3.192 (2.437–4.180)	<0.001	3.644 (3.214–4.132)	<0.001	
Rehospitalization for any cause					
Hospital Frailty Risk Score	1.061 (1.053–1.069)	<0.001	1.061 (1.058–1.064)	<0.001	0.151
Hospital Frailty Risk Category		<0.001		<0.001	
Intermediate risk (5–15)	1.714 (1.526–1.924)	<0.001	1.648 (1.579–1.719)	<0.001	
High risk (>15)	2.722 (2.306–3.214)	<0.001	2.920 (2.739–3.112)	<0.001	
Rehospitalization due to acute myocardial infarction (I21, at subsequent index)					
Hospital Frailty Risk Score	1.050 (1.001–1.101)	0.047	1.079 (1.063–1.095)	<0.001	0.192
Hospital Frailty Risk Category		<0.001		<0.001	
Intermediate risk (5–15)	2.031 (1.183–3.486)	<0.001	2.158 (1.800–2.587)	<0.001	
High risk (>15)	4.483 (2.257–8.904)	<0.001	4.250 (3.305–5.465)	<0.001	
Rehospitalization due to acute renal failure (N17, at subsequent index)					
Hospital Frailty Risk Score	1.073 (1.057–1.088)	<0.001	1.072 (1.064–1.079)	<0.001	0.355
Hospital Frailty Risk Category		<0.001		<0.001	
Intermediate risk (5–15)	1.907 (1.585–2.295)	<0.001	1.813 (1.667–1.971)	<0.001	
High risk (>15)	3.391 (2.639–4.351)	<0.001	3.473 (3.085–3.910)	<0.001	
Rehospitalization due to acute heart failure (I5021, I5031, I5041, I5023, I5033, I5043 at subsequent index)					
Hospital Frailty Risk Score	1.058 (1.044–1.072)	<0.001	1.068 (1.062–1.075)	<0.001	0.160
Hospital Frailty Risk Category		<0.001		<0.001	
Intermediate risk (5–15)	1.738 (1.471–2.054)	<0.001	1.892 (1.742–2.054)	<0.001	
High risk (>15)	2.869 (2.279–3.613)	<0.001	3.509 (3.128–3.936)	<0.001	
Rehospitalization due to stroke or TIA (I63 and G45, at subsequent index)					
Hospital Frailty Risk Score	1.065 (1.021–1.110)	0.003	1.074 (1.059–1.089)	<0.001	0.821
Hospital Frailty Risk Category		0.035		<0.001	
Intermediate risk (5–15)	1.511 (0.927–2.462)	0.097	1.918 (1.619–2.274)	<0.001	
High risk (>15)	4.546 (2.534–8.161)	<0.001	4.061 (3.204–5.146)	<0.001	
Rehospitalization due to acute post-haemorrhagic anaemia (D62, at subsequent index)					
Hospital Frailty Risk Score	1.043 (1.015–1.071)	0.002	1.043 (1.032–1.058)	<0.001	0.806
Hospital Frailty Risk Category		0.001		<0.001	
Intermediate risk (5–15)	1.620 (1.228–2.137)	0.001	1.636 (1.474–1.816)	<0.001	
High risk (>15)	2.049 (1.325–3.168)	0.001	2.266 (1.914–2.683)	<0.001	

For each outcome, two separate (continuous and categorical scale) models were built (low-risk group handled as a reference for category groups; hazard ratio = 1).

spectrum. In addition to the association between frailty and long-term mortality, the current study demonstrates a strong association between frailty and long-term rehospitalizations. Thus, identifying frail patients and stratifying risk categories using the Hospital Frailty Risk Score may also help physicians inform patients and families about the incidence of potential outcomes during the follow-up period. In addition, patients identified as having higher frailty risk could be targeted for strategies such as more intensive follow-up in an effort to prevent costly readmissions.

Previous studies have demonstrated the value of using administrative data in the assessment of frailty based on ICD-9 codes.^{9,15,16,27} Now, the use of ICD-10 codes routinely used in current administrative databases provides hospitals with a systematic method to prospectively screen for frailty risk. The Hospital Frailty Risk Score developed and validated in the UK performs at least as well as or better than existing frailty measures or risk stratification tools.¹⁷ Recently, this score was also externally validated to predict outcomes including long length of stay, 30-day rehospitalization and

1-year mortality in elderly patients from Canada.²⁸ In addition, administrative data include a longitudinal record and demonstrate how the frailty phenotype influences risk indirectly, as evidenced by multiple hospitalizations for conditions related to elevated medical risk rather than geriatric-specific risk (e.g. falls, failure to thrive, etc.). Claims data represent an inexpensive alternative source of data in the absence of prospectively collected information on frailty, which is often not routinely collected in the course of care. The ubiquity of claims data may make it a useful alternative to clinical risk scoring systems in determining procedural outcomes.

There are several potential benefits to routinely identifying older people at risk of adverse clinical outcomes after transcatheter valve therapies. First, we believe that by merging claims-based frailty data with ongoing registries of transcatheter valve therapies, we might enhance the ability to define patient risk and understand long-term outcomes, improve hospital and physician benchmarking, and increase the completeness of data collection by incorporating variables that were not previously being collected. In addition, the score could be applied to hospital information systems prospectively, potentially removing the inter-operator variability and implementation burden associated with manual scoring systems. A uniform and easily implemented method of identifying frail patients can help highlight the magnitude of the challenge associated with their care, enable services to evolve and provide frailty-attuned care, and improve patient- and facility-level outcomes. Identifying frailty in patients with valvular heart disease may also assist physicians in determining appropriateness of treatment and in discussing a patient's prognosis with the patient and family members.

There are notable limitations to the current study. Physiological measures of frailty are not captured in administrative claims data, and thus the claims-based definition of frailty may not comprehensively quantify frailty for all patients. It is also unclear whether the frailty risk score is a truly a measurement of frailty or simply another comorbidity index. The indications and criteria for patient selection are not available, and administrative coding may misclassify some comorbidities and complications compared with prospective collection using standard clinical trial definitions. Future studies could validate the variables used in the frailty score in a small sample of patients undergoing valve therapies. Claims codes also do not always capture the severity of a given condition or its change post-procedure, and we are not able to determine the cause of death. Additionally, because the study population was limited to Medicare beneficiaries, we did not have information on all patients who might have undergone transcatheter valve therapies in the USA. Since the model's discrimination is still modest, the true clinical utility of this score is still unclear, and should be assessed prospectively. Because ICD-10 codes have only been used in the USA since October 2015, we selected a relatively short 3 month lookback period for frailty assessment. As more data become available, longer historical periods for frailty assessment may be useful. Such data would allow for more rigorous assessments regarding changing frailty scores over time—either increases due to accumulation of deficits, or decreases to successful treatment of reversible conditions. Future analyses examining longitudinal changes in frailty and its impact of outcomes are warranted. Also, due to the level of granularity in the claims data, we did not have the variables necessary to calculate traditional risk scores such as the EuroSCORE²⁹ or STS-PROM³⁰ score.

Conclusions

The Hospital Frailty Risk Score, which is readily available and relatively inexpensive to implement, provides hospitals and health systems with a systematic way to identify frailty in patients undergoing transcatheter valve therapies. The score effectively classifies patients at high risk for adverse events including mortality, rehospitalizations and long length of stay. Use of a claims-based frailty score may facilitate the prospective assessment of frailty among patients undergoing transcatheter valve therapies.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Funding

Members of the study team are supported by funding from the National Heart, Lung, and Blood Institute [1F32HL1407-11 (J.B.S.) and R01HS024520-01 (C.S.) and 1R01HL136708-01 (R.W.Y.)].

Conflict of interest: The following authors have no conflicts of interest to declare: H.K., J.J.P., M.R.R., J.B.S., D.S.P., L.R.V., C.S., and E.C. J.J.P. reports grants from Medtronic, Abbott Vascular, and Direct Flow Medical and personal fees from Boston Scientific, Cordis, and Direct Flow Medical, outside the submitted work. R.W.Y. reports investigator initiated grant funding from Abiomed, grant support from Boston Scientific, and consulting from Abbott, Medtronic, and Teleflex, outside the submitted work.

References

- Rodríguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaço Harmand M, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutiérrez-Robledo LM, Rockwood K, Rodríguez Artalejo F, Serviddio G, Vega E. Searching for an operational definition of frailty: a Delphi method based consensus statement. The frailty operative definition-consensus conference project. *J Gerontol A Biol Sci Med Sci* 2013;**68**:62–67.
- Talbot-Hamon C, Afilalo J. Transcatheter aortic valve replacement in the care of older persons with aortic stenosis. *J Am Geriatr Soc* 2017;**65**:693–698.
- Metze C, Matzik A-S, Scherner M, Körber MI, Michels G, Baldus S, Rudolph V, Pfister R. Impact of frailty on outcomes in patients undergoing percutaneous mitral valve repair. *JACC: Cardiovasc Interv* 2017;**10**:1920–1929.
- Afilalo J, Lauck S, Kim DH, Lefèvre T, Piazza N, Lachapelle K, Martucci G, Lamy A, Labinaz M, Peterson MD, Arora RC, Noiseux N, Rassi A, Palacios IF, Généreux P, Lindman BR, Asgar AW, Kim CA, Trnkus A, Morais JA, Langlois Y, Rudski LG, Morin J-F, Popma JJ, Webb JG, Perrault LP. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. *J Am Coll Cardiol* 2017;**70**:689–700.
- Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, Reardon MJ, Yakubov SJ, Adams DH, Cohen DJ. Prediction of poor outcome after transcatheter aortic valve replacement. *J Am Coll Cardiol* 2016;**68**:1868–1877.
- Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, Tsuchikane E, Suzuki T, Otsuka T, Kohsaka S, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Watanabe Y, Hayashida K, Yashima F, Inohara T, Kakefuda Y, Arai T, Yanagisawa R, Tanaka M, Kawakami T, Maekawa Y, Takashi K, Yoshitake A, Iida Y, Yamazaki M, Shimizu H, Yamada Y, Jinzaki M, Tsuruta H, Itabashi Y, Murata M, Kawakami M, Fukui S, Sano M, Fukuda K, Hosoba S, Sato H, Teramoto T, Kimura M, Sago M, Tsunaki T, Watarai S, Tsuzuki M, Irokawa K, Shimizu K, Kobayashi T, Okawa Y, Miyasaka M, Enta Y, Shishido K, Ochiai T, Yamabe T, Noguchi K, Saito S, Kawamoto H, Onishi H, Yabushita H, Mitomo S, Nakamura S, Yamawaki M, Akatsu Y, Honda Y, Takama T, Isotani A, Hayashi M, Kamioka N, Miura M, Morinaga T, Kawaguchi T, Yano M, Hanyu M, Arai Y, Tsubota H, Kudo M, Kuroda Y, Kataoka A, Hioki H, Nara Y, Kawashima H, Nagura F, Nakashima M, Sasaki K, Nishikawa J, Shimokawa T, Harada T, Kozuma K. Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. *Circulation* 2017;**135**:2013–2024.

7. Martin GP, Sperrin M, Ludman PF, deBelder MA, Gunning M, Townend J, Redwood SR, Kadam UT, Buchan I, Mamas MA. Do frailty measures improve prediction of mortality and morbidity following transcatheter aortic valve implantation? An analysis of the UK TAVI registry. *BMJ Open* 2018;**8**:e022543.
8. Rogers T, Alraies MC, Moussa Pacha H, Bond E, Buchanan KD, Steinvil A, Gai J, Torguson R, Ben-Dor I, Satler LF, Waksman R. Clinical frailty as an outcome predictor after transcatheter aortic valve implantation. *Am J Cardiol* 2018;**121**:850–855.
9. Kundi H, Valsdottir LR, Popma JJ, Cohen DJ, Strom JB, Pinto DS, Shen C, Yeh RW. Impact of a claims-based frailty indicator on the prediction of long-term mortality after transcatheter aortic valve replacement in medicare beneficiaries. *Circ Cardiovasc Qual Outcomes* 2018;**11**:e005048.
10. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;**70**:252–289.
11. Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2017;**38**:2739–2791.
12. Van Mieghem NM, Dumonteil N, Chieffo A, Roux Y, van der Boon RMA, Giustino G, Hartman E, Aga Y, de Jong L, Abi Ghanem M, Marcheix B, Cavazza C, Carrié D, Colombo A, Kappetein A-P, de Jaegere PPT, Tchetché D. Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-Rotterdam-Milano-Toulouse In Collaboration Aortic Stenosis survey. *EuroIntervention* 2016;**11**:e1305–e1313.
13. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;**63**:747–762.
14. Grover FL, Vemulapalli S, Carroll JD, Edwards FH, Mack MJ, Thourani VH, Brindis RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM, Peterson ED, Fitzgerald S, Kourtis M, Michaels J, Christensen B, Seward WF, Hewitt K, Holmes DR. 2016 annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Ann Thorac Surg* 2017;**103**:1021–1035.
15. Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-based frailty index. *J Gerontol A Biol Sci Med Sci* 2018;**73**:980–987.
16. Segal JB, Chang H-Y, Du Y, Walston JD, Carlson MC, Varadhan R. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. *Med Care* 2017;**55**:716–722.
17. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, Arora S, Street A, Parker S, Roberts HC, Bardsley M, Conroy S. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. *Lancet* 2018;**391**:1775–1782.
18. Krumholz HM, Nuti SV, Downing NS, Normand S-L, Wang Y. Mortality, hospitalizations, and expenditures for the Medicare population aged 65 years or older, 1999–2013. *JAMA* 2015;**314**:355–365.
19. Schermerhorn J, Buck DB, O'malley AJ, Curran T, McCallum JC, Darling J, Landon BE. Long-term outcomes of abdominal aortic aneurysm in the Medicare population. *N Engl J Med* 2015;**373**:328–338.
20. Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data. *Med Care* 2017;**55**:698–705.
21. Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. *Med Care* 1999;**37**:1128–1139.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988;**44**:837–845.
23. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;**27**:157–172.
24. Schoenenberger AW, Moser A, Bertschi D, Wenaweser P, Windecker S, Carrel T, Stuck AE, Stortecky S. Improvement of risk prediction after transcatheter aortic valve replacement by combining frailty with conventional risk scores. *JACC: Cardiovasc Interv* 2018;**11**:395–403.
25. Aguayo GA, Donneau A-F, Vaillant MT, Schritz A, Franco OH, Stranges S, Malisoux L, Guillaume M, Witte DR. Agreement between 35 published frailty scores in the general population. *Am J Epidemiol* 2017;**186**:420–434.
26. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. *Sci World J* 2001;**1**:323–336.
27. Faurot KR, Jonsson Funk M, Pate V, Brookhart MA, Patrick A, Hanson LC, Castillo WC, Stürmer T. Using claims data to predict dependency in activities of daily living as a proxy for frailty. *Pharmacoepidemiol Drug Saf* 2015;**24**:59–66.
28. McAlister F, van Walraven C. External validation of the Hospital Frailty Risk Score and comparison with the Hospital-patient One-year Mortality Risk Score to predict outcomes in elderly hospitalised patients: a retrospective cohort study. *BMJ Qual Saf* 2019;**28**:284–288.
29. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (Euro SCORE). *Eur J Cardiothorac Surg* 1999;**16**:9–13.
30. Sm, Shahian Dm O, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP; Society of Thoracic Surgeons Quality Measurement Task Force. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. *Ann Thorac Surg* 2009;**88**:23–42.